MACROGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
MACROGENICS, INC. (MGNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $24.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-14
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $21.00K.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $3.00K.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $2.62M, a 2713.98% increase from fiscal 2023.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $93.00K, a 85.33% decline from fiscal 2022.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $634.00K, a 80.79% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $24.00K 10-Q · filed 2026-08-14 | $24.00K derived: sum of 3 quarters · filed 2026-08-14 | $24.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $3.00K 10-Q · filed 2026-05-13 | $3.00K derived: sum of 2 quarters · filed 2026-05-13 | $3.00K derived: sum of 3 quarters · filed 2026-05-13 | $3.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 10-Q · filed 2025-11-12 | $1.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $1.00K derived: sum of 3 quarters · filed 2026-08-14 | $2.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $1.00K derived: sum of 2 quarters · filed 2026-05-13 | $2.00K derived: sum of 3 quarters · filed 2026-05-13 | $699.00K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.00K derived: sum of 2 quarters · filed 2026-03-09 | $699.00K derived: sum of 3 quarters · filed 2026-03-09 | $2.62M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $698.00K derived: sum of 2 quarters · filed 2025-11-12 | $2.62M 10-Q · filed 2025-11-12 | $2.65M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2024-06-30 | $697.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.62M 10-Q · filed 2025-08-14 | $2.65M derived: sum of 3 quarters · filed 2026-03-09 | $2.65M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2024-03-31 | $1.92M 10-Q · filed 2025-05-13 | $1.90M 10-Q · filed 2024-05-09 | $1.95M derived: sum of 2 quarters · filed 2026-03-09 | $1.96M derived: sum of 3 quarters · filed 2026-03-09 | |||
| 2023-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $37.00K derived: sum of 2 quarters · filed 2026-03-09 | $93.00K 10-K · filed 2026-03-09 | $100.00K 10-K · filed 2024-03-07 | |||
| 2023-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $61.00K 10-Q · filed 2024-11-05 | $100.00K 10-Q · filed 2023-11-06 | ||||
| 2023-06-30 | $56.00K 10-Q · filed 2024-08-06 | ||||||
| 2022-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $134.00K derived: sum of 2 quarters · filed 2025-03-20 | $334.00K derived: sum of 3 quarters · filed 2025-03-20 | $634.00K 10-K · filed 2025-03-20 | $600.00K 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $200.00K derived: sum of 2 quarters · filed 2023-11-06 | $500.00K 10-Q · filed 2023-11-06 | $600.00K derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2022-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $500.00K 10-Q · filed 2023-08-09 | $600.00K derived: sum of 3 quarters · filed 2024-03-07 | $2.00M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2022-03-31 | $300.00K 10-Q · filed 2023-05-09 | $400.00K derived: sum of 2 quarters · filed 2024-03-07 | $1.80M derived: sum of 3 quarters · filed 2024-03-07 | $2.20M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.50M derived: sum of 2 quarters · filed 2024-03-07 | $1.90M derived: sum of 3 quarters · filed 2024-03-07 | $3.30M 10-K · filed 2024-03-07 | |||
| 2021-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.80M derived: sum of 2 quarters · filed 2022-11-03 | $3.20M 10-Q · filed 2022-11-03 | $3.60M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.80M 10-Q · filed 2022-08-08 | $2.20M derived: sum of 3 quarters · filed 2023-03-15 | $3.50M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-03-31 | $1.40M 10-Q · filed 2022-05-03 | $1.80M derived: sum of 2 quarters · filed 2023-03-15 | $3.10M derived: sum of 3 quarters · filed 2023-03-15 | $4.60M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2020-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.70M derived: sum of 2 quarters · filed 2023-03-15 | $3.20M derived: sum of 3 quarters · filed 2023-03-15 | $4.30M 10-K · filed 2023-03-15 | |||
| 2020-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $2.80M derived: sum of 2 quarters · filed 2021-11-02 | $3.90M 10-Q · filed 2021-11-02 | $4.00M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $2.60M 10-Q · filed 2021-07-29 | $2.70M derived: sum of 3 quarters · filed 2022-02-24 | $2.90M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-03-31 | $1.10M 10-Q · filed 2021-04-29 | $1.20M derived: sum of 2 quarters · filed 2022-02-24 | $1.40M derived: sum of 3 quarters · filed 2022-02-24 | $2.40M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $300.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.30M derived: sum of 3 quarters · filed 2022-02-24 | $2.90M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $1.20M derived: sum of 2 quarters · filed 2020-11-04 | $2.80M 10-Q · filed 2020-11-04 | $4.00M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $2.60M 10-Q · filed 2020-07-31 | $3.80M derived: sum of 3 quarters · filed 2021-02-25 | $4.10M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $1.60M 10-Q · filed 2020-05-05 | $2.80M derived: sum of 2 quarters · filed 2021-02-25 | $3.10M derived: sum of 3 quarters · filed 2021-02-25 | $6.80M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.50M derived: sum of 2 quarters · filed 2021-02-25 | $5.20M derived: sum of 3 quarters · filed 2021-02-25 | $5.20M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $4.00M derived: sum of 2 quarters · filed 2019-11-06 | $4.00M 10-Q · filed 2019-11-06 | $8.10M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-06-30 | $3.70M 10-Q · filed 2019-07-31 | $3.70M 10-Q · filed 2018-08-07 | $7.80M derived: sum of 3 quarters · filed 2020-02-25 | $8.90M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-03-31 | $3.60M 10-Q · filed 2019-05-01 | $4.10M derived: sum of 2 quarters · filed 2020-02-25 | $5.20M derived: sum of 3 quarters · filed 2020-02-25 | $5.80M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $1.60M derived: sum of 2 quarters · filed 2020-02-25 | $2.20M derived: sum of 3 quarters · filed 2020-02-25 | $4.20M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.70M derived: sum of 2 quarters · filed 2017-11-08 | $3.70M 10-Q · filed 2017-11-08 | $4.90M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $2.60M 10-Q · filed 2017-08-02 | $3.80M derived: sum of 3 quarters · filed 2019-02-26 | $6.20M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | $2.00M 10-Q · filed 2017-05-03 | $3.20M derived: sum of 2 quarters · filed 2019-02-26 | $5.60M derived: sum of 3 quarters · filed 2019-02-26 | $8.50M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $3.60M derived: sum of 2 quarters · filed 2019-02-26 | $6.50M derived: sum of 3 quarters · filed 2019-02-26 | $10.80M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $5.30M derived: sum of 2 quarters · filed 2016-11-02 | $9.60M 10-Q · filed 2016-11-02 | $11.90M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $7.20M 10-Q · filed 2016-08-03 | $9.50M derived: sum of 3 quarters · filed 2018-02-27 | $11.60M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $4.30M 10-Q · filed 2016-05-04 | $6.60M derived: sum of 2 quarters · filed 2018-02-27 | $8.70M derived: sum of 3 quarters · filed 2018-02-27 | $11.90M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $4.40M derived: sum of 2 quarters · filed 2018-02-27 | $7.60M derived: sum of 3 quarters · filed 2018-02-27 | $10.90M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $5.30M derived: sum of 2 quarters · filed 2015-11-04 | $8.60M 10-Q · filed 2015-11-04 | $14.90M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $6.50M 10-Q · filed 2015-08-05 | $12.80M derived: sum of 3 quarters · filed 2017-02-28 | $13.50M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $3.30M 10-Q · filed 2015-05-06 | $9.60M derived: sum of 2 quarters · filed 2017-02-28 | $10.30M derived: sum of 3 quarters · filed 2017-02-28 | $15.30M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $7.00M derived: sum of 2 quarters · filed 2017-02-28 | $12.00M derived: sum of 3 quarters · filed 2017-02-28 | $14.50M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $5.70M derived: sum of 2 quarters · filed 2014-11-12 | $8.20M 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $7.50M 10-Q · filed 2014-08-05 | |||||
| 2014-03-31 | $2.50M 10-Q · filed 2014-05-06 | ||||||
| 2013-12-31 | $5.40M 10-K · filed 2016-02-29 | ||||||
| 2012-12-31 | $271.93K 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |